Search

Your search keyword '"Rodríguez Abreu, Delvys"' showing total 25 results
Start Over Author "Rodríguez Abreu, Delvys" Publication Year Range This year
25 results on '"Rodríguez Abreu, Delvys"'

2. The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy

Author

Gómez Rueda, Ana, Taus, Álvaro, Álvarez Álvarez, Rosa, Bernabé-Caro, Reyes, Chara, Luis, López-Brea, Marta, Vilà, Laia, Sala González, Maria Ángeles, del Barrio Díaz Aldagalán, Anabel, Esteban Herrera, Beatriz, López Castro, Rafael, Álvarez Cabellos, Ruth, Doménech, Marta, Falagan, Sandra, Moreno Vega, Alberto, Aguado, Carlos, Barba, Andrés, Delgado Ureña, Maria Teresa, Isla, Dolores, Bellido Hernández, Lorena, Fírvida Pérez, José Luis, Juan-Vidal, Óscar, Massutí, Bartomeu, Mielgo-Rubio, Xabier, Ortega, Ana Laura, Catot, Silvia, Dómine, Manuel, Escoín-Pérez, Corina, García Navalón, Francisco, Gil-Bazo, Ignacio, Muñoz, Silvia, Rodríguez-Abreu, Delvys, Villatoro Roldán, Rosa María, Alonso-Jáudenes Curbera, Guillermo, León-Mateos, Luis, Padilla, Airam, Paredes Lario, Alfredo, Sánchez-Torres, José Miguel, and Garrido, Pilar

Published
2024
Full Text
View/download PDF

5. Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial

Author

Afanasyev, Sergey, Ahmed, Samreen, Alekshun, Todd, Alves, Gustavo, Anderson, Ian, Araujo, Luiz Henrique, Arkhipov, Alexander, Arora, Arvind, Bai, Jie, Begin, Paul, Belonogov, Aleksandr, Berard, Henri, Berceanu-Ion, Radu, Bernabe Caro, Reyes, Bondarenko, Igor, Bonnet, Reiner, Bosch Barrera, Joaquim, Brocca, Carlos, Bryl, Maciej, Bulotta, Alessandra, Bylicki, Olivier, Calles Blanco, Antonio, Carcereny, Enric, Carvalho, Leticia, Cebotaru, Cristina, Chaft, Jamie, Charu, Veena, Chaves, Fabio, Chen, Jun, Chen, Ke-Neng, Chen, Haiquan, Chen, Qixun, Chen, Kevin, Chiang, Chi-Lu, Chiu, Chao-Hua, Cicenas, Saulius, Ciubotaru, Elena, Ciuleanu, Tudor, Ciurescu, Ioana, Cobb, Patrick, Coetzee, Corlia, Collins, Dearbhaile, Cortinovis, Diego, Costas, Kimberly, Costin, Dan, Cronemberger, Eduardo Henrique, Cuevo, Raymund, Cuffe, Sinead, De Marchi, Pedro Rafael Martins, de Paiva Junior, Tadeu, Delmonte, Angelo, Demedts, Ingel, Deschepper, Koenraad, Dias, Josiane, Dooms, Christophe, Duchemann, Boris, Dutra, Carolina, Duvivier, Herbert, Eigendorff, Ekkehard, Ernani, Vinicius, Faehling, Martin, Faria, Luiza, Fedenko, Alexander, Fernando, Hiran, Ferrara, Roberto, Ferrari, Vittorio, Finley, Gene, Fix, Peter, Flores, Marcos, Fourie, Samuel, Franke, Fabio, Frohling, Klaus-Peter, Furqan, Muhammad, Gal, Cristian, Galamaga, Robert, Ganea, Doina, Ganti, Apar Kishor, Gao, Shugeng, Garassino, Marina, Gentzler, Ryan, Gianni, Luca, Gilli, Marina, Girard, Nicolas, Goranov, Bojidar, Gregorc, Vanesa, Greystoke, Alastair, Grisanti, Salvatore, Grohe, Christian, Guarino, Michael, Guimaraes, Jose Luiz, Guisier, Florian, Halmos, Balazs, Hammoud, Zane Taysir, Han, Ji-Youn, Hegmane, Alinta, Heng, Fook Yew, Horinouchi, Hidehito, Horio, Yoshitsugu, Hu, Jian, Huang, Hsu-Ching, Hui, Rina, Ikeda, Norihiko, Intagliata, Salvatore, Iordan, Ingrid, Jacobs, Conrad, Jain, Kirti, Jain, Sushil, Jiang, Tao, Karaseva, Nina, Kato, Terufumi, Kaywin, Paul, Kazmi, Shayma, Keresztes, Roger, Khan, Sarah, Kim, Jhingook, Kolesnik, Olena, Kolesnik, Oleksii, Kollmeier, Jens, Komiya, Takefumi, Koontz, Michael, Krasnohrud, Yuliia, Kristedja, Timothy, Kryzhanivska, Anna, Kuroda, Hiroaki, Laktionov, Konstantin, Lambrechts, Marc, Lang, Susanne, Langleben, Adrian, Lee, Se-Hoon, Lehmann, Markus, Levchenko, Evgeny, Levenko, Oleh, Li, Shanqing, Liao, Bin-Chi, Liberman, Moishe, Lima, Iane, Liu, Geoffrey, Liu-Dumlao, Theresa, Lo Russo, Giuseppe, Lou, Yan Yan, Lowczak, Anna, Luft, Alexander, Ma, Shaohua, Majem Tarruella, Margarita, Makles, Krytsyna, Martinengo, Gaston, Martinez Marti, Alex, Matias, Danielli, Mazieres, Julien, Mazilu, Laura, Mennecier, Bertrand, Migliorino, Maria Rita, Misleh, Jamal, Molina, Julian, Morbeck, Igor, Mueller, Annette, Muto, Satoshi, Nadal Alforja, Ernest, Nesterova, Alfiya, Nishio, Wataru, Niu, Jiaxin, Novello, Silvia, O'Brien, Mary, O'Day, Steven, Ogliari, Francesca, Okada, Morihito, Pang, Yong Kek, Paramonov, Viktor, Pastor, Andrea, Pawlak, Ireneusz, Piantedosi, Francovito, Pollock, Theodore, Pope, Tony, Puig, Juan, Radhi, Saba, Rao, Suman, Rathnasabapathy, Chenthilmurugan, Reck, Martin, Reinacher-Schick, Anke, Rich, Patricia, Ritgen, Mathias, Rittmeyer, Achim, Roca, Elisa, Rodriguez-Abreu, Delvys, Ruff, Paul, Rybkin, Igor, Saji, Hisashi, Sakao, Yukinori, Sangal, Ashish, Santoro, Armando, Sardenberg, Rodrigo, Savvides, Panayiotis, Scheusan, Roxana, Schiller, Joan, Schumacher, Lana, Serke, Monika, Shim, Byoung Yong, Shimizu, Junichi, Shio, Yutaka, Sibille, Anne, Siegel, Robert, Signorelli, Diego, Smagina, Maria, Sokur, Iryna, Spicer, Jonathan, Srkalovic, Gordan, Stampleman, Laura, Starodub, Alexander, Stencel, Katarzyna, Sugio, Kenji, Surmont, Veerle, Suzuki, Hiroyuki, Tabacof, Jacques, Takamochi, Kazuya, Tan, Lijie, Tanaka, Fumihiro, Tatangelo, Marcelo, Täuscher, Dagmar, Teixeira, Carlos, Thiberville, Luc, Trukhin, Dmytro, Tsai, Chen-Liang, Tsuboi, Masahiro, Ungureanu, Andrei, Ursol, Grygorii, Vanakesa, Tonu, Vansteenkiste, Johan, Varela, Mirta, Villalona-Calero, Miguel, Villaruz, Liza, Vogel, Gunther, Voitko, Nataliia, Wakelee, Heather, Wang, Qun, Wang, Wenxiang, Wang, Chin-Chou, Wang, Sarah, Wehler, Thomas, Weksler, Benny, Wermke, Martin, Wesseler, Claas, Wirtz, Hubert, Wong, Mark, Yan, Xiaolong, Yang, Yue, Yu, Kong Leong, Zasadny, Xavier, Zemaitis, Marius, Zhang, Lanjun, Zhao, Guofang, Zhao, Qing, Zhu, Yuming, Zurawski, Bogdan, Spicer, Jonathan D, Garassino, Marina C, Majem, Margarita, Martinengo, Gastón L, Rodríguez-Abreu, Delvys, Chaft, Jamie E, Yang, Jing, Arunachalam, Ashwini, Keller, Steven M, and Samkari, Ayman

Published
2024
Full Text
View/download PDF

6. Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial

Author

Provencio, Mariano, Nadal, Ernest, Insa, Amelia, García Campelo, Rosario, Casal, Joaquín, Dómine, Manuel, Massuti, Bartomeu, Majem, Margarita, Rodríguez-Abreu, Delvys, Martínez-Martí, Alex, de Castro, Javier, Gómez de Antonio, David, Macia, Iván, Figueroa, Santiago, Fernández Vago, Luís, Calvo, Virginia, Palmero, Ramón, Sierra-Rodero, Belén, Martínez-Toledo, Cristina, Molina-Alejandre, Marta, Serna-Blasco, Roberto, Romero, Atocha, and Cruz-Bermúdez, Alberto

Published
2024
Full Text
View/download PDF

7. Analysis of Diagnostic Delay and its Impact on Lung Cancer Survival: Results From the Spanish Thoracic Tumor Registry

Author

Candal-Pedreira, Cristina, Ruano-Ravina, Alberto, Calvo de Juan, Virginia, Cobo, Manuel, Cantero, Alexandra, Rodríguez-Abreu, Delvys, Estival, Anna, Carcereny, Enric, Hernandez, Ainhoa, López Castro, Rafael, Medina, Andrea, García Campelo, Rosario, Fernández Bruno, Manuel, Barnabé, Reyes, Bosch-Barrera, Joaquim, Massutí, Bartomeu, Dómine, Manuel, Camps, Carlos, Ortega, Ana Laura, and Provencio, Mariano

Published
2024
Full Text
View/download PDF

8. Family history of cancer and lung cancer: Utility of big data and artificial intelligence for exploring the role of genetic risk

Author

Calvo, Virginia, Niazmand, Emetis, Carcereny, Enric, Rodriguez-Abreu, Delvys, Cobo, Manuel, López-Castro, Rafael, Guirado, María, Camps, Carlos, Laura Ortega, Ana, Bernabé, Reyes, Massutí, Bartomeu, Garcia-Campelo, Rosario, del Barco, Edel, Luis González-Larriba, José, Bosch-Barrera, Joaquim, Martínez, Marta, Torrente, María, Vidal, María-Esther, and Provencio, Mariano

Published
2024
Full Text
View/download PDF

10. Describing differences among populations of thoracic tumors patients under and over 80 years: Data analysis from the SLCG thoracic tumor registry

Author

Provencio, Mariano, Cobo, Manuel, Rodriguez-Abreu, Delvys, Carcereny, Enric, Cantero, Alexandra, Calvo, Virginia, López Castro, Rafael, Bernabé, Reyes, Bosch-Barrera, Joaquim, Massutí, Bartomeu, García Campelo, Rosario, Sánchez-Hernández, Alfredo, Laura Ortega, Ana, Guirado, Maria, del Barco, Edel, Camps, Carlos, Casal-Rubio, Joaquin, Dómine, Manuel, Angeles Sala, Mª, Padilla, Airam, Luís González Larriba, Jose, and de Asís Aparisi, Francisco

Published
2024
Full Text
View/download PDF

12. Comparison of Clinical and Genetic Characteristics Between Younger and Older Lung Cancer Patients

Author

Candal-Pedreira, Cristina, Ruano-Ravina, Alberto, Calvo de Juan, Virginia, Cobo, Manuel, Trigo, José Manuel, Rodríguez-Abreu, Delvys, Estival, Anna, Carcereny, Enric, Cucurull, Marc, López Castro, Rafael, Medina, Andrea, García Campelo, Rosario, Cordeiro González, Patricia, Sánchez-Gastaldo, Amparo, Bosch-Barrera, Joaquim, Massutí, Bartomeu, Dómine, Manuel, Camps, Carlos, Ortega, Ana Laura, Sánchez-Hernández, Alfredo, Guirado Risueño, María, del Barco Morillo, Edel, Garrido Fernández, Alberto, and Provencio, Mariano

Published
2024
Full Text
View/download PDF

13. SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

Author

Abdel-Karim, Isam, Abdelsalam, Mahmoud, Addeo, Alfredo, Aguado, Carlos, Alexander, Patrick, Alt, Jürgen, Azzi, Georges, Balaraman, Rama, Biesma, Bonne, Blackhall, Fiona, Bohnet, Sabine, Boleti, Ekaterini, Borghaei, Hossein, Bradbury, Penelope, Brighenti, Matteo, Campbell, Nicholas, Campbell, Toby, Canon, Jean-Luc, Cappuzzo, Federico, Costa, Enric Carcereny, Cavanna, Luigi, Cetnar, Jeremy, Chella, Antonio, Chouaid, Christos, Christoph, Daniel, Castán, Javier Cortés, Dakhil, Shaker, de Castro Carpeño, Francisco Javier, de Marinis, Filippo, Delmonte, Angelo, Demedts, Ingel, Demey, Wim, Dits, Joyce, del Pilar Diz Taín, Maria, Gómez, Manuel Dómine, Dorius, Timothy, Dumoulin, Daphne, Duruisseaux, Michaël, Eaton, Keith, González, Emilio Esteban, Evans, Devon, Faehling, Martin, Farrell, Nicholas, Feinstein, Trevor, Font, Enriqueta Felip, Garcia Campelo, Maria Rosario, Garon, Edward, Garrido López, María Pilar, Germonpré, Paul, Gersten, Todd, Cao, Maria Gonzalez, Gopaluni, Srivalli, Greillier, Laurent, Grossi, Francesco, Guisier, Florian, Gurubhagavatula, Sarada, Calderón, Vanesa Gutiérrez, Hakimian, David, Hall, Richard, Jr., Hao, Desirée, Harris, Ronald, Hashemi, Sayed, He, Kai, Hendriks, Lizza, Huang, Chao, Ibrahim, Emad, Jain, Sharad, Johnson, Melissa, Jones, Benjamin, Jones, Monte, Juan Vidal, Óscar José, Juergens, Rosalyn, Kaderbhai, Courèche, Kastelijn, Elisabeth A (Lisanne), Keresztes, Roger, Kio, Ebenezer, Kokowski, Konrad, Konduri, Kartik, Kulkarni, Swati, Kuon, Jonas, Kurkjian, Carla, Labbé, Catherine, Lerner, Rachel, Lim, Farah, Madroszyk-Flandin, Anne, Marathe, Omkar, Martincic, Danko, McClay, Edward, McIntyre, Kristi, Mekhail, Tarek, Misino, Andrea, Molinier, Olivier, Morabito, Alessandro, Morócz, Éva, Müller, Veronika, Nagy, Tünde, Nguyen, Anthony V., Nidhiry, Emmanuel, Okazaki, Ian, Ortega-Granados, Ana Laura, Ostoros, Gyula, Oubre, David, Owen, Scott, Pachipala, Krishna, Park, David, Patel, Pareshkumar, Percent, Ivor, Pérol, Maurice, Peters, Solange, Piet, Berber, Planchard, David, Polychronis, Andreas, Aix, Santiago Ponce, Pons-Tostivint, Elvire, Popat, Sanjaykumar, Pulla, Mariano Provencio, Quantin, Xavier, Quéré, Gilles, Rafique, Noman, Ramaekers, Ryan, Reck, Martin, Reiman, Anthony, Reinmuth, Niels, Reynolds, Craig, Rodríguez-Abreu, Delvys, Romano, Gianpiero, Roque, Tammy, Salzberg, Matthew, Sanborn, Rachel, Sandiego, Sergio, Schaefer, Eric, Schreeder, Marshall, Seetharamu, Nagashree, Seneviratne, Lasika, Shah, Purvi, Shunyakov, Leonid, Slater, Dennis, Parra, Hector Soto, Stigt, Johannes, Stilwill, Joseph, Su, Jingdong, Surmont, Veerle, Swink, Alicia, Szalai, Zsuzsanna, Talbot, Toby, Garcia, Alvaro Taus, Theelen, Willemijn, Thompson, Jonathan, Tiseo, Marcello, Uprety, Dipesh, Uyeki, James, van der Leest, Kornelius Cor, Van Ho, Anthony, van Putten, John, Estévez, Sergio Vázquez, Veatch, Andrea, Vergnenègre, Alain, Ward, Patrick, Weise, Amy, Weiss, Matthias, Whitehurst, Matthew, Zai, Silvia, Zalcman, Gérard, Zuniga, Richard, Borghaei, H., de Marinis, F., Dumoulin, D., Reynolds, C., Theelen, W.S.M.E., Percent, I., Gutierrez Calderon, V., Johnson, M.L., Madroszyk-Flandin, A., Garon, E.B., He, K., Planchard, D., Reck, M., Popat, S., Herbst, R.S., Leal, T.A., Shazer, R.L., Yan, X., Harrigan, R., and Peters, S.

Published
2024
Full Text
View/download PDF

14. Blood tumor mutational burden and response to pembrolizumab plus chemotherapy in non–small cell lung cancer: KEYNOTE-782

Author

Bar, Jair, primary, Esteban, Emilio, additional, Rodríguez-Abreu, Delvys, additional, Aix, Santiago Ponce, additional, Szalai, Zsuzsanna, additional, Felip, Enriqueta, additional, Gottfried, Maya, additional, Provencio, Mariano, additional, Robinson, Andrew, additional, Fülöp, Andrea, additional, Rao, Suman Bannur, additional, Camidge, D. Ross, additional, Speranza, Giovanna, additional, Townson, Steven M., additional, Kobie, Julie, additional, Ayers, Mark, additional, Dettman, E.J., additional, Hunkapiller, Nathan, additional, McDaniel, Robert, additional, Jung, Byoungsok, additional, Burkhardt, David, additional, Mauntz, Ruth, additional, and Csőszi, Tibor, additional

Published
2024
Full Text
View/download PDF

15. Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial

Author

Spicer, Jonathan D, Garassino, Marina C, Wakelee, Heather, Liberman, Moishe, Kato, Terufumi, Tsuboi, Masahiro, Lee, Se-Hoon, Chen, Ke-Neng, Dooms, Christophe, Majem, Margarita, Eigendorff, Ekkehard, Martinengo, Gastón L, Bylicki, Olivier, Rodríguez-Abreu, Delvys, Chaft, Jamie E, Novello, Silvia, Yang, Jing, Arunachalam, Ashwini, Keller, Steven M, Samkari, Ayman, Gao, Shugeng, Afanasyev, Sergey, Ahmed, Samreen, Alekshun, Todd, Alves, Gustavo, Anderson, Ian, Araujo, Luiz Henrique, Arkhipov, Alexander, Arora, Arvind, Bai, Jie, Begin, Paul, Belonogov, Aleksandr, Berard, Henri, Berceanu-Ion, Radu, Bernabe Caro, Reyes, Bondarenko, Igor, Bonnet, Reiner, Bosch Barrera, Joaquim, Brocca, Carlos, Bryl, Maciej, Bulotta, Alessandra, Bylicki, Olivier, Calles Blanco, Antonio, Carcereny, Enric, Carvalho, Leticia, Cebotaru, Cristina, Chaft, Jamie, Charu, Veena, Chaves, Fabio, Chen, Jun, Chen, Ke-Neng, Chen, Haiquan, Chen, Qixun, Chen, Kevin, Chiang, Chi-Lu, Chiu, Chao-Hua, Cicenas, Saulius, Ciubotaru, Elena, Ciuleanu, Tudor, Ciurescu, Ioana, Cobb, Patrick, Coetzee, Corlia, Collins, Dearbhaile, Cortinovis, Diego, Costas, Kimberly, Costin, Dan, Cronemberger, Eduardo Henrique, Cuevo, Raymund, Cuffe, Sinead, De Marchi, Pedro Rafael Martins, de Paiva Junior, Tadeu, Delmonte, Angelo, Demedts, Ingel, Deschepper, Koenraad, Dias, Josiane, Dooms, Christophe, Duchemann, Boris, Dutra, Carolina, Duvivier, Herbert, Eigendorff, Ekkehard, Ernani, Vinicius, Faehling, Martin, Faria, Luiza, Fedenko, Alexander, Fernando, Hiran, Ferrara, Roberto, Ferrari, Vittorio, Finley, Gene, Fix, Peter, Flores, Marcos, Fourie, Samuel, Franke, Fabio, Frohling, Klaus-Peter, Furqan, Muhammad, Gal, Cristian, Galamaga, Robert, Ganea, Doina, Ganti, Apar Kishor, Gao, Shugeng, Garassino, Marina, Gentzler, Ryan, Gianni, Luca, Gilli, Marina, Girard, Nicolas, Goranov, Bojidar, Gregorc, Vanesa, Greystoke, Alastair, Grisanti, Salvatore, Grohe, Christian, Guarino, Michael, Guimaraes, Jose Luiz, Guisier, Florian, Halmos, Balazs, Hammoud, Zane Taysir, Han, Ji-Youn, Hegmane, Alinta, Heng, Fook Yew, Horinouchi, Hidehito, Horio, Yoshitsugu, Hu, Jian, Huang, Hsu-Ching, Hui, Rina, Ikeda, Norihiko, Intagliata, Salvatore, Iordan, Ingrid, Jacobs, Conrad, Jain, Kirti, Jain, Sushil, Jiang, Tao, Karaseva, Nina, Kato, Terufumi, Kaywin, Paul, Kazmi, Shayma, Keresztes, Roger, Khan, Sarah, Kim, Jhingook, Kolesnik, Olena, Kolesnik, Oleksii, Kollmeier, Jens, Komiya, Takefumi, Koontz, Michael, Krasnohrud, Yuliia, Kristedja, Timothy, Kryzhanivska, Anna, Kuroda, Hiroaki, Laktionov, Konstantin, Lambrechts, Marc, Lang, Susanne, Langleben, Adrian, Lee, Se-Hoon, Lehmann, Markus, Levchenko, Evgeny, Levenko, Oleh, Li, Shanqing, Liao, Bin-Chi, Liberman, Moishe, Lima, Iane, Liu, Geoffrey, Liu-Dumlao, Theresa, Lo Russo, Giuseppe, Lou, Yan Yan, Lowczak, Anna, Luft, Alexander, Ma, Shaohua, Majem Tarruella, Margarita, Makles, Krytsyna, Martinengo, Gaston, Martinez Marti, Alex, Matias, Danielli, Mazieres, Julien, Mazilu, Laura, Mennecier, Bertrand, Migliorino, Maria Rita, Misleh, Jamal, Molina, Julian, Morbeck, Igor, Mueller, Annette, Muto, Satoshi, Nadal Alforja, Ernest, Nesterova, Alfiya, Nishio, Wataru, Niu, Jiaxin, Novello, Silvia, O'Brien, Mary, O'Day, Steven, Ogliari, Francesca, Okada, Morihito, Pang, Yong Kek, Paramonov, Viktor, Pastor, Andrea, Pawlak, Ireneusz, Piantedosi, Francovito, Pollock, Theodore, Pope, Tony, Puig, Juan, Radhi, Saba, Rao, Suman, Rathnasabapathy, Chenthilmurugan, Reck, Martin, Reinacher-Schick, Anke, Rich, Patricia, Ritgen, Mathias, Rittmeyer, Achim, Roca, Elisa, Rodriguez-Abreu, Delvys, Ruff, Paul, Rybkin, Igor, Saji, Hisashi, Sakao, Yukinori, Sangal, Ashish, Santoro, Armando, Sardenberg, Rodrigo, Savvides, Panayiotis, Scheusan, Roxana, Schiller, Joan, Schumacher, Lana, Serke, Monika, Shim, Byoung Yong, Shimizu, Junichi, Shio, Yutaka, Sibille, Anne, Siegel, Robert, Signorelli, Diego, Smagina, Maria, Sokur, Iryna, Spicer, Jonathan, Srkalovic, Gordan, Stampleman, Laura, Starodub, Alexander, Stencel, Katarzyna, Sugio, Kenji, Surmont, Veerle, Suzuki, Hiroyuki, Tabacof, Jacques, Takamochi, Kazuya, Tan, Lijie, Tanaka, Fumihiro, Tatangelo, Marcelo, Täuscher, Dagmar, Teixeira, Carlos, Thiberville, Luc, Trukhin, Dmytro, Tsai, Chen-Liang, Tsuboi, Masahiro, Ungureanu, Andrei, Ursol, Grygorii, Vanakesa, Tonu, Vansteenkiste, Johan, Varela, Mirta, Villalona-Calero, Miguel, Villaruz, Liza, Vogel, Gunther, Voitko, Nataliia, Wakelee, Heather, Wang, Qun, Wang, Wenxiang, Wang, Chin-Chou, Wang, Sarah, Wehler, Thomas, Weksler, Benny, Wermke, Martin, Wesseler, Claas, Wirtz, Hubert, Wong, Mark, Yan, Xiaolong, Yang, Yue, Yu, Kong Leong, Zasadny, Xavier, Zemaitis, Marius, Zhang, Lanjun, Zhao, Guofang, Zhao, Qing, Zhu, Yuming, and Zurawski, Bogdan

Abstract

At the first interim analysis of the KEYNOTE-671 trial, adding perioperative pembrolizumab to neoadjuvant chemotherapy significantly improved event-free survival in participants with early-stage non-small-cell lung cancer (NSCLC). We report overall survival and health-related quality of life outcomes from the second interim analysis.

Published
2024
Full Text
View/download PDF

16. CD8+ NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent/refractory diffuse large B cell lymphoma

Author

Instituto de Salud Carlos III, Universidad de Sevilla, Celgene, Junta de Andalucía, Hontecillas-Prieto, Lourdes, García-Domínguez, D. J., Palazón-Carrión, Natalia, Martín García-Sancho, Alejandro, Nogales Fernández, Esteban, Jiménez-Cortegana, Carlos, Sánchez-León, María L., Silva-Romeiro, Silvia, Flores-Campos, Rocío, Carnicero-González, Fernando, Rios-Herranz, Eduardo, Cruz-Vicente, Fátima de la, Rodríguez-García, Guillermo, Fernández-Álvarez, Rubén, Martínez-Banaclocha, Natividad, Gumà-Padrò, Josep, Gómez Codina, José, Salar-Silvestre, Antonio, Rodríguez-Abreu, Delvys, Gálvez-Carvajal, Laura, Labrador, Jorge, Guirado-Risueño, María, Provencio, Mariano, Sánchez-Beato, Margarita, Marylene, Lejeune, Álvaro Naranjo, Tomás, Casanova-Espinosa, María, Rueda-Domínguez, Antonio, Sánchez-Margalet, Víctor, Cruz-Merino, Luis de la, Instituto de Salud Carlos III, Universidad de Sevilla, Celgene, Junta de Andalucía, Hontecillas-Prieto, Lourdes, García-Domínguez, D. J., Palazón-Carrión, Natalia, Martín García-Sancho, Alejandro, Nogales Fernández, Esteban, Jiménez-Cortegana, Carlos, Sánchez-León, María L., Silva-Romeiro, Silvia, Flores-Campos, Rocío, Carnicero-González, Fernando, Rios-Herranz, Eduardo, Cruz-Vicente, Fátima de la, Rodríguez-García, Guillermo, Fernández-Álvarez, Rubén, Martínez-Banaclocha, Natividad, Gumà-Padrò, Josep, Gómez Codina, José, Salar-Silvestre, Antonio, Rodríguez-Abreu, Delvys, Gálvez-Carvajal, Laura, Labrador, Jorge, Guirado-Risueño, María, Provencio, Mariano, Sánchez-Beato, Margarita, Marylene, Lejeune, Álvaro Naranjo, Tomás, Casanova-Espinosa, María, Rueda-Domínguez, Antonio, Sánchez-Margalet, Víctor, and Cruz-Merino, Luis de la

Abstract

Diffuse large B cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma worldwide. DLBCL is an aggressive disease that can be cured with upfront standard chemoimmunotherapy schedules. However, in approximately 35-40% of the patients DLBCL relapses, and therefore, especially in this setting, the search for new prognostic and predictive biomarkers is an urgent need. Natural killer (NK) are effector cells characterized by playing an important role in antitumor immunity due to their cytotoxic capacity and a subset of circulating NK that express CD8 have a higher cytotoxic function. In this substudy of the R2-GDP-GOTEL trial, we have evaluated blood CD8+ NK cells as a predictor of treatment response and survival in relapsed/refractory (R/R) DLBCL patients.

Published
2024

17. DataSheet_1_CD8+ NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent/refractory diffuse large B cell lymphoma.pdf

Author

Hontecillas-Prieto, Lourdes [0000-0002-0582-3386], García-Domínguez, D. J. [0000-0001-8150-2747], Flores-Campos, Rocío [0000-0002-2563-4136], Hontecillas-Prieto, Lourdes, García-Domínguez, D. J., Palazón-Carrión, Natalia, Martín García-Sancho, Alejandro, Nogales Fernández, Esteban, Jiménez-Cortegana, Carlos, Sánchez-León, María L., Silva-Romeiro, Silvia, Flores-Campos, Rocío, Carnicero-González, Fernando, Rios-Herranz, Eduardo, Cruz-Vicente, Fátima de la, Rodríguez-García, Guillermo, Fernández-Álvarez, Rubén, Martínez-Banaclocha, Natividad, Gumà-Padrò, Josep, Gómez Codina, José, Salar-Silvestre, Antonio, Rodríguez-Abreu, Delvys, Gálvez-Carvajal, Laura, Labrador, Jorge, Guirado-Risueño, María, Provencio, Mariano, Sánchez-Beato, Margarita, Marylene, Lejeune, Álvaro Naranjo, Tomás, Casanova-Espinosa, María, Rueda-Domínguez, Antonio, Sánchez-Margalet, Víctor, Cruz-Merino, Luis de la, Hontecillas-Prieto, Lourdes [0000-0002-0582-3386], García-Domínguez, D. J. [0000-0001-8150-2747], Flores-Campos, Rocío [0000-0002-2563-4136], Hontecillas-Prieto, Lourdes, García-Domínguez, D. J., Palazón-Carrión, Natalia, Martín García-Sancho, Alejandro, Nogales Fernández, Esteban, Jiménez-Cortegana, Carlos, Sánchez-León, María L., Silva-Romeiro, Silvia, Flores-Campos, Rocío, Carnicero-González, Fernando, Rios-Herranz, Eduardo, Cruz-Vicente, Fátima de la, Rodríguez-García, Guillermo, Fernández-Álvarez, Rubén, Martínez-Banaclocha, Natividad, Gumà-Padrò, Josep, Gómez Codina, José, Salar-Silvestre, Antonio, Rodríguez-Abreu, Delvys, Gálvez-Carvajal, Laura, Labrador, Jorge, Guirado-Risueño, María, Provencio, Mariano, Sánchez-Beato, Margarita, Marylene, Lejeune, Álvaro Naranjo, Tomás, Casanova-Espinosa, María, Rueda-Domínguez, Antonio, Sánchez-Margalet, Víctor, and Cruz-Merino, Luis de la

Abstract

[Background] Diffuse large B cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma worldwide. DLBCL is an aggressive disease that can be cured with upfront standard chemoimmunotherapy schedules. However, in approximately 35-40% of the patients DLBCL relapses, and therefore, especially in this setting, the search for new prognostic and predictive biomarkers is an urgent need. Natural killer (NK) are effector cells characterized by playing an important role in antitumor immunity due to their cytotoxic capacity and a subset of circulating NK that express CD8 have a higher cytotoxic function. In this substudy of the R2-GDP-GOTEL trial, we have evaluated blood CD8+ NK cells as a predictor of treatment response and survival in relapsed/refractory (R/R) DLBCL patients., [Methods] 78 patients received the R2-GDP schedule in the phase II trial. Blood samples were analyzed by flow cytometry. Statistical analyses were carried out in order to identify the prognostic potential of CD8+ NKs at baseline in R/R DLBCL patients., [Results] Our results showed that the number of circulating CD8+ NKs in R/R DLBCL patients were lower than in healthy donors, and it did not change during and after treatment. Nevertheless, the level of blood CD8+ NKs at baseline was associated with complete responses in patients with R/R DLBCL. In addition, we also demonstrated that CD8+ NKs levels have potential prognostic value in terms of overall survival in R/R DLBCL patients., [Conclusion] CD8+ NKs represent a new biomarker with prediction and prognosis potential to be considered in the clinical management of patients with R/R DLBCL., [Clinical trial registration] https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001620-29 EudraCT, ID:2014-001620-29.

Published
2024

18. Trial Protocol 1 from A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy

Author

Weiss, Sarah A., primary, Sznol, Mario, primary, Shaheen, Montaser, primary, Berciano-Guerrero, Miguel-Ángel, primary, Couselo, Eva Muñoz, primary, Rodríguez-Abreu, Delvys, primary, Boni, Valentina, primary, Schuchter, Lynn M., primary, Gonzalez-Cao, Maria, primary, Arance, Ana, primary, Wei, Wei, primary, Ganti, Apar Kishor, primary, Hauke, Ralph J., primary, Berrocal, Alfonso, primary, Iannotti, Nicholas O., primary, Hsu, Frank J., primary, and Kluger, Harriet M., primary

Published
2024
Full Text
View/download PDF

19. Supplementary Data 1 from A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy

Author

Weiss, Sarah A., primary, Sznol, Mario, primary, Shaheen, Montaser, primary, Berciano-Guerrero, Miguel-Ángel, primary, Couselo, Eva Muñoz, primary, Rodríguez-Abreu, Delvys, primary, Boni, Valentina, primary, Schuchter, Lynn M., primary, Gonzalez-Cao, Maria, primary, Arance, Ana, primary, Wei, Wei, primary, Ganti, Apar Kishor, primary, Hauke, Ralph J., primary, Berrocal, Alfonso, primary, Iannotti, Nicholas O., primary, Hsu, Frank J., primary, and Kluger, Harriet M., primary

Published
2024
Full Text
View/download PDF

20. Data from A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy

Author

Weiss, Sarah A., primary, Sznol, Mario, primary, Shaheen, Montaser, primary, Berciano-Guerrero, Miguel-Ángel, primary, Couselo, Eva Muñoz, primary, Rodríguez-Abreu, Delvys, primary, Boni, Valentina, primary, Schuchter, Lynn M., primary, Gonzalez-Cao, Maria, primary, Arance, Ana, primary, Wei, Wei, primary, Ganti, Apar Kishor, primary, Hauke, Ralph J., primary, Berrocal, Alfonso, primary, Iannotti, Nicholas O., primary, Hsu, Frank J., primary, and Kluger, Harriet M., primary

Published
2024
Full Text
View/download PDF

21. Supplementary Figure 1 from A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy

Author

Weiss, Sarah A., primary, Sznol, Mario, primary, Shaheen, Montaser, primary, Berciano-Guerrero, Miguel-Ángel, primary, Couselo, Eva Muñoz, primary, Rodríguez-Abreu, Delvys, primary, Boni, Valentina, primary, Schuchter, Lynn M., primary, Gonzalez-Cao, Maria, primary, Arance, Ana, primary, Wei, Wei, primary, Ganti, Apar Kishor, primary, Hauke, Ralph J., primary, Berrocal, Alfonso, primary, Iannotti, Nicholas O., primary, Hsu, Frank J., primary, and Kluger, Harriet M., primary

Published
2024
Full Text
View/download PDF

22. CD8+ NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDPGOTEL trial in recurrent/refractory diffuse large B cell lymphoma.

Author

Hontecillas-Prieto, Lourdes, García-Domínguez, Daniel J., Palazón-Carrión, Natalia, García-Sancho, Alejandro Martín, Nogales-Fernández, Esteban, Jiménez-Cortegana, Carlos, Sánchez-León, María L., Silva-Romeiro, Silvia, Flores-Campos, Rocío, Carnicero-González, Fernando, Ríos-Herranz, Eduardo, de la Cruz-Vicente, Fátima, Rodríguez-García, Guillermo, Fernández-Álvarez, Rubén, Martínez-Banaclocha, Natividad, Gumà-Padrò, Josep, Gómez-Codina, José, Salar-Silvestre, Antonio, Rodríguez-Abreu, Delvys, and Gálvez-Carvajal, Laura

Subjects
B cell lymphoma, DIFFUSE large B-cell lymphomas, CD8 antigen, LENALIDOMIDE, BIOMARKERS, KILLER cells
Abstract

Background: Diffuse large B cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma worldwide. DLBCL is an aggressive disease that can be cured with upfront standard chemoimmunotherapy schedules. However, in approximately 35-40% of the patients DLBCL relapses, and therefore, especially in this setting, the search for new prognostic and predictive biomarkers is an urgent need. Natural killer (NK) are effector cells characterized by playing an important role in antitumor immunity due to their cytotoxic capacity and a subset of circulating NK that express CD8 have a higher cytotoxic function. In this substudy of the R2-GDPGOTEL trial, we have evaluated blood CD8+ NK cells as a predictor of treatment response and survival in relapsed/refractory (R/R) DLBCL patients. Methods: 78 patients received the R2-GDP schedule in the phase II trial. Blood samples were analyzed by flow cytometry. Statistical analyses were carried out in order to identify the prognostic potential of CD8+ NKs at baseline in R/R DLBCL patients. Results: Our results showed that the number of circulating CD8+ NKs in R/R DLBCL patients were lower than in healthy donors, and it did not change during and after treatment. Nevertheless, the level of blood CD8+ NKs at baseline was associated with complete responses in patients with R/R DLBCL. In addition, we also demonstrated that CD8+ NKs levels have potential prognostic value in terms of overall survival in R/R DLBCL patients. Conclusion: CD8+ NKs represent a new biomarker with prediction and prognosis potential to be considered in the clinical management of patients with R/R DLBCL. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

24. CD8+ NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent/refractory diffuse large B cell lymphoma.

Author

Hontecillas-Prieto L, García-Domínguez DJ, Palazón-Carrión N, Martín García-Sancho A, Nogales-Fernández E, Jiménez-Cortegana C, Sánchez-León ML, Silva-Romeiro S, Flores-Campos R, Carnicero-González F, Ríos-Herranz E, de la Cruz-Vicente F, Rodríguez-García G, Fernández-Álvarez R, Martínez-Banaclocha N, Gumà-Padrò J, Gómez-Codina J, Salar-Silvestre A, Rodríguez-Abreu D, Gálvez-Carvajal L, Labrador J, Guirado-Risueño M, Provencio-Pulla M, Sánchez-Beato M, Marylene L, Álvaro-Naranjo T, Casanova-Espinosa M, Rueda-Domínguez A, Sánchez-Margalet V, and de la Cruz-Merino L

Subjects
Humans, Biomarkers, CD8-Positive T-Lymphocytes pathology, Killer Cells, Natural pathology, Lenalidomide therapeutic use, Neoplasm Recurrence, Local pathology, Pathologic Complete Response, Lymphoma, Large B-Cell, Diffuse pathology, Lymphoma, Non-Hodgkin
Abstract

Background: Diffuse large B cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma worldwide. DLBCL is an aggressive disease that can be cured with upfront standard chemoimmunotherapy schedules. However, in approximately 35-40% of the patients DLBCL relapses, and therefore, especially in this setting, the search for new prognostic and predictive biomarkers is an urgent need. Natural killer (NK) are effector cells characterized by playing an important role in antitumor immunity due to their cytotoxic capacity and a subset of circulating NK that express CD8 have a higher cytotoxic function. In this substudy of the R2-GDP-GOTEL trial, we have evaluated blood CD8+ NK cells as a predictor of treatment response and survival in relapsed/refractory (R/R) DLBCL patients., Methods: 78 patients received the R2-GDP schedule in the phase II trial. Blood samples were analyzed by flow cytometry. Statistical analyses were carried out in order to identify the prognostic potential of CD8+ NKs at baseline in R/R DLBCL patients., Results: Our results showed that the number of circulating CD8+ NKs in R/R DLBCL patients were lower than in healthy donors, and it did not change during and after treatment. Nevertheless, the level of blood CD8+ NKs at baseline was associated with complete responses in patients with R/R DLBCL. In addition, we also demonstrated that CD8+ NKs levels have potential prognostic value in terms of overall survival in R/R DLBCL patients., Conclusion: CD8+ NKs represent a new biomarker with prediction and prognosis potential to be considered in the clinical management of patients with R/R DLBCL., Clinical Trial Registration: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001620-29 EudraCT, ID:2014-001620-29., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision., (Copyright © 2024 Hontecillas-Prieto, García-Domínguez, Palazón-Carrión, Martín García-Sancho, Nogales-Fernández, Jiménez-Cortegana, Sánchez-León, Silva-Romeiro, Flores-Campos, Carnicero-González, Ríos-Herranz, de la Cruz-Vicente, Rodríguez-García, Fernández-Álvarez, Martínez-Banaclocha, Gumà-Padrò, Gómez-Codina, Salar-Silvestre, Rodríguez-Abreu, Gálvez-Carvajal, Labrador, Guirado-Risueño, Provencio-Pulla, Sánchez-Beato, Marylene, Álvaro-Naranjo, Casanova-Espinosa, Rueda-Domínguez, Sánchez-Margalet and de la Cruz-Merino.)

Published
2024
Full Text
View/download PDF

25. A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy.

Author

Weiss SA, Sznol M, Shaheen M, Berciano-Guerrero MÁ, Couselo EM, Rodríguez-Abreu D, Boni V, Schuchter LM, Gonzalez-Cao M, Arance A, Wei W, Ganti AK, Hauke RJ, Berrocal A, Iannotti NO, Hsu FJ, and Kluger HM

Subjects
Humans, Antibodies, Monoclonal adverse effects, Disease Progression, Antineoplastic Combined Chemotherapy Protocols adverse effects, Nivolumab adverse effects, Melanoma pathology
Abstract

Purpose: Disease progression during or after anti-PD-1-based treatment is common in advanced melanoma. Sotigalimab is a CD40 agonist antibody with a unique epitope specificity and Fc receptor binding profile optimized for activation of CD40-expressing antigen-presenting cells. Preclinical data indicated that CD40 agonists combined with anti-PD1 could overcome resistance to anti-PD-1., Patients and Methods: We conducted a multicenter, open-label, phase II trial to evaluate the combination of sotigalimab 0.3 mg/kg and nivolumab 360 mg every 3 weeks in patients with advanced melanoma following confirmed disease progression on a PD-1 inhibitor. The primary objective was to determine the objective response rate (ORR)., Results: Thirty-eight subjects were enrolled and evaluable for safety. Thirty-three were evaluable for activity. Five confirmed partial responses (PR) were observed for an ORR of 15%. Two PRs are ongoing at 45.9+ and 26+ months, whereas the other three responders relapsed at 41.1, 18.7, and 18.4 months. The median duration of response was at least 26 months. Two additional patients had stable disease for >6 months. Thirty-four patients (89%) experienced at least one adverse event (AE), and 13% experienced a grade 3 AE related to sotigalimab. The most common AEs were pyrexia, chills, nausea, fatigue, pruritus, elevated liver function, rash, vomiting, headache, arthralgia, asthenia, myalgia, and diarrhea. There were no treatment-related SAEs, deaths, or discontinuation of sotigalimab due to AEs., Conclusions: Sotigalimab plus nivolumab had a favorable safety profile consistent with the toxicity profiles of each agent. The combination resulted in durable and prolonged responses in a subset of patients with anti-PD-1-resistant melanoma, warranting further evaluation in this setting. See related commentary by Wu and Luke, p. 9., (©2023 The Authors; Published by the American Association for Cancer Research.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results